Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Joseph Vinetz
University of California, San Diego, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
GlimmerDX, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Vinetz and his spouse are co-founders of GlimmerDX and hold (b)(4) equity interest combined. In addition, Dr. Vinetz is the Chief Scientific Officer. The mission of the company is to produce ultrahigh affinity antibody sensors for the diagnosis of infectious disease. This project is to develop new, clinically actionable diagnostics tests using fundamental biological scientific methods combined with clinical/field studies in contrasting epidemiological contexts in Peru and Sri Lanka.
Addressing the Global Burden of Leptospirosis in Two Endemic Countries
The proposed U19 ICIDR Program is focused on human infection and disease by Leptospira. Our overall approach is to use fundamental biological scientific methods combined with clinical/field studies in contrasting epidemiological contexts in Peru and Sri Lanka to develop new, clinically relevant diagnostic tests. This work will guide new efforts to determine the Global Burden of Disease due to Leptospirosis, of both national domestic and military importance, and internationally. Project 1: Developing Diagnostics for Assessing Leptospirosis Burden of Disease in Peru Project Leader: Jessica Ricaldi, MD, PhD, DTM&H DESCRIPTION (as provided by applicant): Leptospirosis is among the world's most important zoonotic infectious diseases, annually affecting an estimated 868,000 people globally, with an estimated case fatality rate of 5-10%. Important gaps remain in translating recent fundamental molecular advances in studies of Leptospira and leptospirosis to public health approaches to preventing and ameliorating this infectious disease. The long-term goal of this project is to develop and validate new tools for the diagnosis of leptospirosis, in order to be able to address the true global burden of disease. In this study we propose to develop new field study sites in contrasting places to determine nationally as well as regionally important serovars (Aim 1). These studies will allow us to obtain well-characterized isolates to determine national and regional repertoire of Leptospira in a country of known diversity (Aim 2). The collaboration with Dr. Agampodi and the group in Sri Lanka will allow us to evaluate even more geographically distinct environments. Therefore this South-South collaboration build upon well-established scientific relationships is a key aspect of this project, in addition to the research capacity building and cross-disciplinary research outcomes. Lastly we propose to develop ultra-sensitive, broad-spectrum, rapid, inexpensive tests based on 1) high affinity monoclonal antibodies to lipopolysaccharide; 2) antigen detection by using targets identified using protein arrays. PUBLIC RELEVANCE: Leptospirosis is a globally important infectious disease-affecting people globally. The goal of this project is to develop and validate diagnostic tests that can be used worldwide, independent of the predominant regional leptospiral serovars. The impact of this project is broad, and has the ultimate goal of determining the true global burden of disease for leptospirosis.
Filed on October 12, 2016.
Tell us what you know about Joseph Vinetz's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Joseph Vinetz filed other conflict of interest disclosures with the NIH:
Name | Institution | Type | Company | Disclosed Value |
---|---|---|---|---|
Joseph Vinetz | University of California, San Diego | Conflict of Interest | LeptoX, Inc. | $0 - $4,999 |
Joseph Vinetz | University of California, San Diego | Conflict of Interest | LeptoX, Inc. | $0 - $4,999 |
Joseph Vinetz | Yale University | Conflict of Interest | LeptoX, Inc. | Value cannot be readily determined |
Joseph Vinetz | University of California, San Diego | Conflict of Interest | GlimmerDX, LLC | Value cannot be readily determined |
Joseph Vinetz | University of California, San Diego | Conflict of Interest | GlimmerDX, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.